Meeting
2024 ASCO Genitourinary Cancers Symposium
A phase 1 study of IO102-IO103 vaccine plus pembrolizumab in patients with BCG-intolerant or unresponsive non-muscle invasive bladder cancer (NMIBC).
Authors
Sumana Veeravelli
University of California, Davis Comprehensive Cancer Center, Sacramento, CA
Sumana Veeravelli , Marc Dall'era , Shuchi Gulati , Nicholas Mitsiades , Rashmi Verma , Christopher P. Evans , Thenappan Chandrasekar , Arta Monir Monjazeb , Primo N Lara Jr., Mamta Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05843448
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS716)
DOI
10.1200/JCO.2024.42.4_suppl.TPS716
Abstract #
TPS716
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
First Author: Anders Mellemgaard
Poster
2023 ASCO Annual Meeting
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
First Author: Colette Shen
Poster
2023 ASCO Annual Meeting
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
First Author: Hizra Farrukh
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane